DISRUPTIVE ADDED VALUE

UNIQUE APPROACH TO EVALUATE EFFICACY OF NOVEL THERAPEUTICS IN RECORD TIME

The pharmaceutical industry is under increased pressure to advance development of new therapies in a fast and efficient manner, whilst ensuring safety and quality of data.

ARENSIA’s playing field

A critical segment of the drug development process is the PROOF OF CONCEPT phase, namely the „first-in-patient“ (Phase IB or IIA) clinical trials which aim to detect the first efficacy signal of new therapies in the given targeted patient population/disease.

The data resulting out of the PROOF-OF-CONCEPT trials are the foundation for deciding on whether to stop or to continue the research of new therapeutic options before making any large investments to advance the drugs to later phases of development.

Industry challenge

An increasing number of clinical trials need expert research facilities able to manage sophisticated Phase I/II PROOF OF CONCEPT protocols with innovative compounds in patient populations. Their protocols imply complex medical assessments, intensive PK/PD procedures and require a strong infrastructure for hospitalization.

The typical clinical trial sites are lacking dedicated personnel, and this personnel often lacks expertise to execute such complex research. As a consequence, to perform PROOF OF CONCEPT clinical trials (which require relatively low numbers of patients, ranging 12 to 200), pharmaceutical companies must involve a multitude of clinical trial sites to compensate these shortcomings. High costs, delays and quality issues ensue.

ARENSIA solution

At ARENSIA, we understood industry needs, and to meet them, we have built over the last decade our proprietary network of research clinics in 8 countries, serving numerous therapeutic areas.

All ARENSIA Clinics are entirely dedicated to speeding up PROOF OF CONCEPT trials, and have all systems in place to ensure highest safety standards for patients, as well as quality of data.

Typical clinical trial sites are overcrowded by daily hospital duties, lack of staff (especially research-oriented personnel), competition for same populations and long timelines for contract negotiations. ARENSIA Clinics achieve a remarcable time reduction through unrivalled recruiting performance! The shortened time and the different setup of concentrating effort on few ARENSIA Clinics (instead of the traditional high number of sites) lead to an overall budget reduction of at least 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial.

93% repeat business proves that ARENSIA’s value proposition is the long expected disruptive break-through in time and cost! This has allowed our continuous growth, while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, as well as global CROs.